Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H18O6 |
Molecular Weight | 354.3533 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CO[C@H](C3=CC=C4OCOC4=C3)[C@@]1([H])CO[C@H]2C5=CC=C6OCOC6=C5
InChI
InChIKey=PEYUIKBAABKQKQ-WZBLMQSHSA-N
InChI=1S/C20H18O6/c1-3-15-17(25-9-23-15)5-11(1)19-13-7-22-20(14(13)8-21-19)12-2-4-16-18(6-12)26-10-24-16/h1-6,13-14,19-20H,7-10H2/t13-,14-,19-,20+/m0/s1
Molecular Formula | C20H18O6 |
Molecular Weight | 354.3533 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugfuture.com/chemdata/asarinin.html | https://www.ncbi.nlm.nih.gov/pubmed/23282922https://www.ncbi.nlm.nih.gov/pubmed/24232457 | http://www.sciencedirect.com/science/article/pii/S1756464615004065 | https://www.ncbi.nlm.nih.gov/pubmed/25267105 | https://www.ncbi.nlm.nih.gov/pubmed/22818712
Sources: http://www.drugfuture.com/chemdata/asarinin.html | https://www.ncbi.nlm.nih.gov/pubmed/23282922https://www.ncbi.nlm.nih.gov/pubmed/24232457 | http://www.sciencedirect.com/science/article/pii/S1756464615004065 | https://www.ncbi.nlm.nih.gov/pubmed/25267105 | https://www.ncbi.nlm.nih.gov/pubmed/22818712
ASARININ, (+)- ((+)-episesamin), an abundant lignan
in sesame seed, has been identified as an active principle
in an aqueous extract of Lindera obtusiloba (Japanese
Spicebush) with a strong anti-inflammatory
potential. (+)-episesamin (ES) is known to block the TNF-α-induced mitogenic VSMC response. Protective effect of (+)-episesamin against PDGF-BB-induced activation of vascular smooth muscle cells is mediated by induction of haem oxygenase-1 and inhibition of mitogenic signalling. ES interferes with inflammation-associated VSMC activation and subsequent decreased proliferation and migration due to anti-oxidative properties and impaired activation of NF-ĸB, known contributors to atherogenesis. These results suggest ES as a complemental treatment of VSMC specific vascular diseases such as atherosclerosis. (+)-Episesamin inhibits adipogenesis and exerts anti-inflammatory effects in 3T3-L1 (pre)adipocytes by sustained Wnt signaling, down-regulation of PPARγ and induction of iNOS. (+)-episesamin seems to be the active drug in the L. obtusiloba extract being responsible for the inhibition of adipogenesis and, thus, should be evaluated as a novel potential complementary treatment for obesity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0042554 |
|||
Target ID: CHEMBL248 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24232457 |
|||
Target ID: CHEMBL2823 |
|||
Target ID: CHEMBL612641 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24687738 |
|||
Target ID: CHEMBL613088 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24687738 |
|||
Target ID: CHEMBL614982 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24687738 |
|||
Target ID: CHEMBL614987 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24687738 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
PubMed
Title | Date | PubMed |
---|---|---|
[Synthesis of DL-asarinin and DL-sesamin]. | 1957 Jan |
|
Comparative study of sesame lignans (sesamin, episesamin and sesamolin) affecting gene expression profile and fatty acid oxidation in rat liver. | 2009 Feb |
|
(±)-Asarinin. | 2013 Jan |
|
New benzo[c]phenanthridine and benzenoid derivatives, and other constituents from Zanthoxylum ailanthoides: Effects on neutrophil pro-inflammatory responses. | 2013 Nov 13 |
|
The lignan (+)-episesamin interferes with TNF-α-induced activation of VSMC via diminished activation of NF-ĸB, ERK1/2 and AKT and decreased activity of gelatinases. | 2015 Mar |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:18:39 GMT 2023
by
admin
on
Sat Dec 16 05:18:39 GMT 2023
|
Record UNII |
C3RVX72NMG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
101612
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | |||
|
C054125
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | |||
|
DTXSID201033462
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | |||
|
C3RVX72NMG
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | |||
|
133-03-9
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | |||
|
m2082
Created by
admin on Sat Dec 16 05:18:39 GMT 2023 , Edited by admin on Sat Dec 16 05:18:39 GMT 2023
|
PRIMARY | Merck Index |